metabolic health market – The Milli Chronicle

Saturday, December 13, 2025

Latest:

Saudi Arabia Strengthens Local Pharma Innovation with Riyadh Generic Drugs Conference 2025
Saudi Arabia Rises in Global Universal Health Coverage Index with Strong Vision 2030 Reforms
Global Harmony Takes Center Stage as China’s Chorus Choir Debuts in Saudi Arabia
Lululemon CEO exit sparks optimism for brand reset and renewed growth
US regulator grants initial approval for major crypto firms to launch national trust banks

Factual Version of a Story

Asia Featured News

NewsDesk Milli Chronicle December 12, 2025December 12, 2025 affordable semaglutide, chronic disease management, diabetes drug pricing, diabetes treatment India, glycemic control therapy, healthcare innovation India, heart health medication, India healthcare growth, India obesity care, Indian pharmaceutical market, kidney risk reduction drug, metabolic drug competition, metabolic health market, Novo Nordisk India, obesity treatment trends, Ozempic India launch, semaglutide generics, type 2 diabetes population, weekly diabetes injection, weight loss treatment India

Ozempic Debuts in India as Affordable Weekly Option for Growing Diabetes Care

Ozempic made its highly anticipated entry into the Indian market with pricing designed to improve access for millions managing type

Featured News World

NewsDesk Milli Chronicle November 8, 2025November 8, 2025 antitrust regulations, biopharma growth, Eli Lilly competition, healthcare innovation, metabolic health market, Metsera deal, Metsera shareholder meeting, Novo Nordisk withdrawal, obesity drug market, obesity treatment innovation, Pfizer $10 billion merger, Pfizer acquisition, Pfizer strategic expansion., pharmaceutical investments, U.S. biotech mergers, weight-loss drug development

Pfizer secures $10 billion Metsera deal after Novo Nordisk withdraws

Pfizer’s $10 billion acquisition of Metsera marks a major victory for the U.S. pharmaceutical giant, strengthening its position in the